Zoster Sine Herpete Diagnosis and Management

Risk Factors and Prevention

The lifetime risk of any VZV reactivation, including ZSH, is 20-30% in the general population, with substantially higher rates in older adults and immunocompromised individuals 1
Older adults are at higher risk of ZSH due to declining cell-mediated immunity, allowing VZV reactivation 1
Immunocompromised individuals, including those on immunosuppressive therapy, with HIV, or undergoing cancer treatment, are at increased risk of ZSH 2
The American College of Immunology recommends vaccination for all adults ≥50 years to prevent both typical herpes zoster and atypical presentations like ZSH, with a demonstrated 97.2% efficacy in preventing VZV reactivation 1, 2, 4

High clinical suspicion is warranted when patients present with dermatomal pain patterns, especially in older adults or immunocompromised individuals, even without visible lesions, with a strength of evidence supporting the importance of early recognition 1, 2
The Centers for Disease Control and Prevention recommends considering ZSH in the differential diagnosis of unexplained dermatomal pain, especially in older or immunocompromised patients, and pursuing laboratory confirmation rather than waiting for a rash that will never appear 1, 2